TargeTrust Biotech. Ltd.

Real Early Cancer Screening, Detecting Cancer Therapy Resistance & Guiding Precision Dosing, in Real-time 

Product Value

      Our product can greatly reduce the global cancer problem. It is the world’s only product to:

1. Detect real early cancer to cut tumor away. Make cancer cured easily.

2. Detect cancer therapy resistance in real-time. Guide correct therapy. Prevent patients from taking ineffective drugs.

3. Guide precision dosing in real-time. Reduce drug side-effects in cancer therapy.

4. Detect early cancer relapse to timely treat it.

5. Make real-time cancer action detection possible.

6. Applicable to all cancer types and all therapy methods.

Unmet Medical Needs:

1. Most cancers are detected too late, rendering cancer hard to treat.

2. Cancer therapy resistance: Many drugs become ineffective in cancer therapy; patients take ineffective drugs, delaying therapy; hightly lethal.

3. Drug side-effects: Common in cancer therapy; patients uncomfortable; may disrupt therapy; cause other diseseases, sometime lethal.

4. Current methods (CT scan, CTC, ctDNA common liquid biopsy, NGS….etc) assay cancer and cancer therapy response at cancer progression stage (increased tumor size, tumor invade other organs), these results take many months; too late, delaying therapy. Current methods are unable to detect small tumors to detect real early cancer, rendering cancer hard to treat.

 Our Solution:    

     Tumor signal transductions stimulate cancer progression, and it takes time only 1 hour and circulates. We creates a novel medical field "Tumor Signal Transduction-Liquid Biopsy" to assay tumor signals in blood. It can detect emerging cancer formation, cancer progression, cancer relapse, therapy resistance, and drug precision dosing, in real-time. It makes real-time cancer action detection possible. 

Our product is applicable for real early cancer screening, to find early tumor to cut it away, making cancer cured easily 

Product Clinical Trials

Cancer Screening:

Cancers have oncogene thus have high blood phospho-CSE1L levels. Healthy people don’t have cancer and oncogene, their blood p-CSE1L is undetectable. Assay 36 colorectal cancer blood and 36 healthy blood. p-CSE1L only occur in cancer blood, Not in normal blood.

Cancer Therapy Monitoring: 

Long-term follow-up of six cancer patients. Each patent was assayed at different time courses post-therapy. Totally 32 times of follow-up and assays.  Single blinded clinical trials.

Competitive Analysis

Market Size

Current global cancer liquid biopsy market are: screening 40%; therapy selection 26%;  recurrence assay 24%; therapy monitoring 8%; others 1% (Roots Analysis, www.rootsanalysis.com, 2020). Current methods are less useful for detecting early cancer, therapy monitoring & guiding precision dosing, thus the markets are very small. Our product is especially useful for early cancer screening, therapy monitoring, early cancer relapse assay, & guiding precision dosing. The market and revenue will be very big; near 45%, 2,700 M USD/year.

Other Projects

Tumor biomarker phospho-CSE1L:

(1) It is highly expressed in most cancer types.

(2) It is a microvesicle membrane protein that accumulated in tumor tissue.

(3) Oncogene results in CSE1L phosphorylation.

(4) Tumor cells express oncogene thus have high phospho-CSE1L; normal cells don’t express oncogene, phospho-CSE1L is undetectable.

Our invention can also be used in:

1.   Targeted contrast agent for imaging-guided tumor surgery

2.   Targeted antibody-drug conjugates 

3.   Targeted magnetic hyperthermia cancer therapy

4.   Targeted imaging probe for early cancer detection, guiding precise radiotherapy, and monitoring radiotherapy response

Product slide

https://docs.google.com/presentation/d/13n4tX69p7RKCNOlFObeESXwu55TYUXQn_T4uRLgdkZ4/edit?usp=sharing

Contact: jiangmwd@gmail.com